Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Amylin Forms Global Alliance in Obesity Drug Development; TEDMED’s Show Will Go On, Sequenom Sued for Civil Fraud, & More San Diego Biotech News
|
Bruce V. Bigelow |
11/05/09 |
San Diego
|
|
Amylin Strikes $1 Billion Deal with Takeda to Co-Develop Weight Loss Drugs
|
Luke Timmerman |
11/02/09 |
San Diego
|
|
Amylin, Lilly’s Byetta Wins FDA Approval as Standalone Therapy, Without Combo Drugs
|
Luke Timmerman |
10/30/09 |
San Diego
|
|
Diabetes drug from San Diego’s Amylin caught up in Aussie Brouhaha
|
Denise Gellene |
10/27/09 |
San Diego
|
|
Eastbourne Dumps Amylin Shares, Illumina Inks Licensing Deal, Avanir Releases Pseudobulbar Affect Data, & More San Diego Life Sciences News
|
Denise Gellene |
10/15/09 |
San Diego
|
|
Eastbourne Capital Dumps Entire Stake in Amylin After Partial Victory in Proxy Battle
|
Luke Timmerman |
10/09/09 |
San Diego
|
|
Amylin CEO, Putting Boardroom Coup Behind Him, Turns Up Heat on New Diabetes Drug
|
Luke Timmerman |
09/29/09 |
San Diego
|
|
The San Diego Biotech Survival Index: Local Firms Make Strong Rebound In First Half of 2009
|
Luke Timmerman |
09/23/09 |
San Diego
|
|
Arena Obesity Drug Passes Second Trial, Aims to Sell Safe Option for Millions of People
|
Luke Timmerman |
09/18/09 |
San Diego
|
|
Amylin Targets Obesity, Tioga Shows Virtual Business Model, Roka Bioscience Spins Off Gen-Probe, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
09/17/09 |
San Diego
|
|
Amylin, Dark Horse of the Obesity Drug Battle, Follows Fast Behind Arena, Orexigen
|
Luke Timmerman |
09/14/09 |
San Diego
|
|
Amylin and Biogen Idec Make Board Changes, Inovio Catches Wave of Investor ‘Swine Flu’ Fervor, Ligand Buys Neurogen, & Other San Diego Life Sciences News
|
Bruce V. Bigelow |
08/27/09 |
San Diego
|
|
Former Novartis CEO Elected as Amylin Chairman
|
Bruce V. Bigelow |
08/25/09 |
San Diego
|
|
Domain Raises a $500M VC Fund, Dissident Prods Amylin Again, Avanir Passes Pivotal Test, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
08/13/09 |
San Diego
|
|
In Aftermath of Proxy Fight Amylin Pharmaceuticals Investor Expresses Concern Over Empty Board Chair Seat
|
Bruce V. Bigelow |
08/07/09 |
San Diego
|
|
Anadys Cuts Jobs, Obesity Drug Developers Show Intriguing Results, Trius Antibiotic Passes Key Test, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/11/09 |
San Diego
|
|
Amylin’s Would-Be Savior, Once-Weekly Diabetes Shot, Shows Two-Year Benefit
|
Luke Timmerman |
06/07/09 |
San Diego
|
|
Amylin Dissidents Win Board Seats, Targeted Genetics’ Troubles Raise Gene Therapy Concerns, Celladon Eyes Partnership, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/04/09 |
San Diego
|
|
Biogen Idec Showdown with Carl Icahn Culminates in Shareholder Vote Today
|
Luke Timmerman |
06/03/09 |
Boston
|
|
Amylin Founder Ted Greene, In Exclusive Interview, Upbeat About Outcome of Proxy Battle
|
Bruce V. Bigelow |
06/02/09 |
San Diego
|
|
Amylin Chairman, Lead Director Ousted as Dissidents Gain Two Board Seats
|
Luke Timmerman |
06/02/09 |
San Diego
|
|
Amylin Pharmaceuticals Gets New Directors (But Who Are They?), Ophthonix and Vical Raise Capital, Metabasis Cuts Back—Again, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
05/28/09 |
San Diego
|
|
Amylin’s Dissident Shareholders Gain Influence on Board
|
Bruce V. Bigelow |
05/27/09 |
San Diego
|
|
Amylin Shareholders Vote Today in Battle to Influence Board
|
Bruce V. Bigelow |
05/27/09 |
San Diego
|
|
Shareholder Showdown at Amylin Headquarters
|
Juha-Pekka Tikka |
05/26/09 |
San Diego
|
|
Amylin Nears Endgame With Icahn, Sciele Pharma Declares Victory in Buyout, Nanogen Files Bankruptcy, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
05/21/09 |
San Diego
|
|
Icahn Wants to Fix Amylin First, Not Sell on the Cheap, Alex Denner Says
|
Luke Timmerman |
05/19/09 |
San Diego
|
|
Amylin Dissidents Win More Support
|
Luke Timmerman |
05/18/09 |
San Diego
|
|
Amylin Co-Founder Ted Greene Explains His Switch in Proxy Battle
|
Bruce V. Bigelow |
05/18/09 |
San Diego
|
|
Amylin Dissidents Ought to Win Proxy Fight, Influential Advisory Firm Says
|
Luke Timmerman |
05/15/09 |
San Diego
|
|
Page 1 of
3 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
